Compare SLB & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLB | EW |
|---|---|---|
| Founded | 1926 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5B | 46.0B |
| IPO Year | 1996 | 1999 |
| Metric | SLB | EW |
|---|---|---|
| Price | $51.42 | $78.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 21 |
| Target Price | $51.49 | ★ $96.47 |
| AVG Volume (30 Days) | ★ 20.5M | 4.6M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | 1.67 |
| Revenue | ★ $30,440,000,000.00 | $5,439,500,000.00 |
| Revenue This Year | $5.40 | $12.43 |
| Revenue Next Year | $4.37 | $9.89 |
| P/E Ratio | ★ $21.94 | $47.32 |
| Revenue Growth | ★ 9.46 | N/A |
| 52 Week Low | $31.11 | $65.94 |
| 52 Week High | $52.40 | $87.89 |
| Indicator | SLB | EW |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 43.97 |
| Support Level | $48.84 | $75.51 |
| Resistance Level | $52.40 | $80.42 |
| Average True Range (ATR) | 1.45 | 2.42 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 80.30 | 44.90 |
SLB is the world's premier oilfield-services company as measured by market share. While the industry is largely fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies in which it operates. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today, it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: core, digital, and new energy businesses. Over three-fourths of its revenue base is tied to international markets, while the company boasts roughly $3 billion in digital-related revenue.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.